Let the Buyer Beware: Challenges with Online Pharmacies
Recent articles have shed light on an issue of concern about counterfeits for patients who take imatinib myselate as part of their treatment for GIST.
Recent articles have shed light on an issue of concern about counterfeits for patients who take imatinib myselate as part of their treatment for GIST.
Dr. Yoon-Koo Kang of the Asan Medical Center, Seoul, Korea, discusses the results of his team's study on the effect of L-carnitine in muscle cramps in GIST patients who are on imatinib.
This discussion reviewed CRCI in general, and how a person who is being treated for GIST could be affected. We also talked about strategies that can help ameliorate CRCI, new research on CRCI and GIST. we also gave advice on how cancer survivors can best cope with and care for themselves during this unusual global health event.
The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.
Patient-reported outcomes is a buzz-phase that we hear a lot these days. At the Life Raft Group, I was recently in a meeting where we were discussing patient-reported outcomes, the LRG registry and patient-powered [...]
Many people love the warm sun, beaches, and gardens, but along with those beautiful summer days comes the threat of sun damage. What does this mean for GIST patients?
A significant finding from a newly published study in JAMA Oncology, indicates that nearly one-fourth of GIST patients with advanced disease initially treated with imatinib will survive for ten years or more. The study, [...]
On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]
On February 1, 2016, there was a commercial launch of the generic version of imatinib mesylate (Gleevec) which is approved for CML patients by the FDA. As the first to file for generic marketing [...]
A few weeks ago, Chris Carley lost his battle with GIST and the Life Raft Group lost one of its heroes. He was 73 and had been fighting his battle with GIST since 1995. He [...]